Excellence in Antibody and ELISA Development
Excellence in Antibody and ELISA Development

Our Scientific Advisory Board

The Scientific Advisory Board, established in December 2017, will provide BioGenes with significant expertise and experience throughout the whole drug development and manufacturing value chain to help strengthen and extend the BioGenes’ position in the field of biopharmaceuticals

Board Members:

Prof. Dr. Frank F. Bier

Dept. Biosystems Integration and Process Automatisation, Fraunhofer IZI-BB, Potsdam-Golm

Founder of the Molecular Bioanalytics branch of the Fraunhofer Institute for Biomedical Engineering (Fraunhofer IBMT). In 2003, he was appointed Chair of Applied Bioelectronics and Biochip Technology at the University of Potsdam. Since 2014 he is the Head of the Department Biosystems Integration and Process Automatisation of the newly formed branch Fraunhofer Institute for Cell Therapy and Immunology, Biotechnology and Bioproduction (Fraunhofer IZI-BB) in Potsdam-Golm, Germany.

Prof. Dr. Hans Henning von Horsten

Industrial Biomanufacturing, HTW-Berlin University of Applied Sciences, Berlin

Co-inventor of several patents and pending patent applications for the biomanufacturing business. He was among the key inventors of ProBioGen’s GlymaxX antibody engineering technology that was out licensed to Boehringer-Ingelheim, Novartis, Thermo-Fisher Scientific and several other drug developers. Hans Henning von Horsten is also Head of the Working Group Biotechnology at the Berlin-Brandenburg branch of the VDI Association of German Engineers.

Dr. Jens Knauer

Method Dev. Virology Testing QC, IDT Biologika GmbH, Dessau-Rosslau

Dr. Knauer has a strong background in GLP/GMP contract research, method development and as a Principal Investigator in several clinical trials. Before joining IDT Biologika GmbH, he was involved in the development and validation of immunological assays at the Fraunhofer Institute for Cell Therapy and Immunology where he was also instrumental in building a GLP laboratory for immuno-toxicological assays.

Dr. Wieland Wolf

CEO of ProBioGen AG

Probiogen AG is an internationally operating Contract Development and Manufacturing Organization (CDMO). He has three decades of experience in the biopharmaceutical industry. Wieland Wolf was involved in pioneering product registrations at Bioferon GmbH, headed a production unit for API and parenteral dosage forms at the same company, and was responsible for the biotechnology division of the Rentschler Group, which he led through its transformation from a product-oriented enterprise into an established service provider and contract manufacturing organization (CMO). Wieland Wolf is the President of the European Association for Pharma Biotechnology and a member of the Board of Trustees of the Fraunhofer Institute for Interfacial Engineering and Biotechnology (Fraunhofer IGB) in Stuttgart, Germany.